About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:5582314
Allelic
Composition
Krastm4Tyj/Kras+
Tg(Mx1-cre)1Cgn/0
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm4Tyj mutation (7 available); any Kras mutation (36 available)
Tg(Mx1-cre)1Cgn mutation (6 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mice survive for a median of 84 days after pIpC injection

hematopoietic system
• increase in the number of proliferating splenocytes in pIpC treated mice; most of these proliferating cells are Mac1+/Gr1 lo or Ter119+
• mice treated with pIpC show large numbers of proliferating splenic Ter199+ cells, indicating that erythropoiesis is ineffective (J:87429)
• the erythroid progenitor compartment is massively expanded in the spleen of pIpC treated mice (J:115071)
• pIpC treated mice show normal numbers of early erythroid cells in the bone marrow but a paucity of all the more mature TER119 hi populations, indicating an inefficient transition from TER119- to TER119 hi stages of erythropoiesis (J:115071)
• bone marrow from pIpC treated mice forms abnormally large BFU-E colonies characterized by both erythropoietin-independent growth and hypersensitivity to erythropoietin (J:115071)
• spleen of pIpC treated mice contains increase of immature CD71 hi TER119-/lo cells and large numbers of TER119 hi erythroblasts (J:115071)
• pIpC injected mice develop a myeloproliferative disease with excess monocytes
• bone marrow mononuclear cells from pIpC treated mice form significant numbers of colony-forming unit granulocyte-macrophage (CFU-GM) colonies in the absence of exogenous cytokines while wild-type cells do not
• CFU-GM shows an increased proliferative response without added cytokines (9-fold) or to GM-CSF (19-fold increase) or IL-3 (37-fold increase)
• mice show abundant myeloid cells at various stages of differentiation after pIpC injection
• pups injected with pIpC develop anemia (J:87429)
• however, normal platelet counts are seen in pIpC injected mice (J:87429)
• in pIpC treated mice
• in pIpC treated mice
• in pIpC treated mice
• pups injected with pIpC at 21 days of age develop progressive leukocytosis that is evident 3 weeks after pIpC injection
• mice show an expanded population of Mac-1+, Gr-1 lo cells, indicating an expansion of immature monocytic cells
• in pIpC treated mice
• spleens of pIpC-treated moribund mice are massively enlarged (J:87429)
• in pIpC treated mice (J:115071)

immune system
• increase in the number of proliferating splenocytes in pIpC treated mice; most of these proliferating cells are Mac1+/Gr1 lo or Ter119+
• pIpC injected mice develop a myeloproliferative disease with excess monocytes
• bone marrow mononuclear cells from pIpC treated mice form significant numbers of colony-forming unit granulocyte-macrophage (CFU-GM) colonies in the absence of exogenous cytokines while wild-type cells do not
• CFU-GM shows an increased proliferative response without added cytokines (9-fold) or to GM-CSF (19-fold increase) or IL-3 (37-fold increase)
• mice show abundant myeloid cells at various stages of differentiation after pIpC injection
• pups injected with pIpC at 21 days of age develop progressive leukocytosis that is evident 3 weeks after pIpC injection
• mice show an expanded population of Mac-1+, Gr-1 lo cells, indicating an expansion of immature monocytic cells
• spleens of pIpC-treated moribund mice are massively enlarged (J:87429)
• in pIpC treated mice (J:115071)

liver/biliary system
• pIpC injected mice show moderate hepatomegaly with myeloid infiltration, particularly in periportal areas

cellular
• increase in the number of proliferating splenocytes in pIpC treated mice; most of these proliferating cells are Mac1+/Gr1 lo or Ter119+

homeostasis/metabolism
• serum erythropoietin levels are increased in proportion to anemia in pIpC treated mice


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
02/11/2020
MGI 6.14
The Jackson Laboratory